CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 13 enrolled
Drug / intervention
p-inulindietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02572882
NCT02572882N/ACompleted
CompareCT.gov

A Multi-center Study to Characterize the Gut Microbiome of Individuals With End-stage Renal Disease Treated With Maintenance Hemodialysis, and to Explore Effects of P-inulin on the Gut Microbiome

University of Pennsylvania·interventional·Posted Oct 9, 2015·Updated Oct 20, 2022

In Brief

A clinical study evaluating p-inulin for End-Stage Renal Disease and Gut Microbiome Dysbiosis. Completed, enrolled 13 participants across 4 sites.

Detailed Summary

The Microbiome trial is a non-randomized, open-label, sequential, multi-center study of p-inulin for patients with hemodialysis-dependent end-stage renal disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd-Stage Renal Disease, Gut Microbiome Dysbiosis
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Brigham and Women's Hospital, George Washington University, Vanderbilt University, University of Washington

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 9, 2015
Enrollment StartOct 1, 2015
Primary CompletionJan 24, 2017
Study CompletionJan 1, 2019
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.7 years ago

Interventions

p-inulindietary

12 week self-administered treatment phase